Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis.

Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, Bordón C, Charman SA, Katneni K, Schultz T, Burrows JN, Hinrichs DJ, Meunier B, Carruthers VB, Riscoe MK.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15936-41. Epub 2012 Sep 10.

2.

Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii.

Alday PH, Bruzual I, Nilsen A, Pou S, Winter R, Ben Mamoun C, Riscoe MK, Doggett JS.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01866-16. doi: 10.1128/AAC.01866-16. Print 2017 Feb.

3.

Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo.

Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R.

PLoS Negl Trop Dis. 2008 Mar 5;2(3):e190. doi: 10.1371/journal.pntd.0000190.

4.

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, Maly DJ.

J Med Chem. 2016 Jul 14;59(13):6531-46. doi: 10.1021/acs.jmedchem.6b00760. Epub 2016 Jul 1.

5.

Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.

Doggett JS, Ojo KK, Fan E, Maly DJ, Van Voorhis WC.

Antimicrob Agents Chemother. 2014 Jun;58(6):3547-9. doi: 10.1128/AAC.01823-13. Epub 2014 Mar 31.

6.

Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.

Stec J, Fomovska A, Afanador GA, Muench SP, Zhou Y, Lai BS, El Bissati K, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Sommervile C, Woods S, Roberts CW, Rice D, Prigge ST, McLeod R, Kozikowski AP.

ChemMedChem. 2013 Jul;8(7):1138-60. doi: 10.1002/cmdc.201300050. Epub 2013 Jun 14.

7.

Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance.

McFadden DC, Tomavo S, Berry EA, Boothroyd JC.

Mol Biochem Parasitol. 2000 Apr 30;108(1):1-12.

PMID:
10802314
8.

Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis.

Andrade RM, Chaparro JD, Capparelli E, Reed SL.

PLoS Negl Trop Dis. 2014 Jul 31;8(7):e2973. doi: 10.1371/journal.pntd.0002973. eCollection 2014.

9.

Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach.

Kortagere S, Mui E, McLeod R, Welsh WJ.

J Comput Aided Mol Des. 2011 May;25(5):403-11. doi: 10.1007/s10822-011-9420-6. Epub 2011 Feb 26.

PMID:
21359560
10.

Ketolide ABT-773 is active against Toxoplasma gondii.

Khan AA, Araujo FG, Craft JC, Remington JS.

J Antimicrob Chemother. 2000 Sep;46(3):489-92.

PMID:
10980181
11.

Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii.

Hegewald J, Gross U, Bohne W.

Mol Biochem Parasitol. 2013 Jul;190(1):6-15. doi: 10.1016/j.molbiopara.2013.05.008. Epub 2013 Jun 5.

PMID:
23747278
12.

Sterculic Acid and Its Analogues Are Potent Inhibitors of Toxoplasma gondii.

Hao P, Alaraj IQ, Dulayymi JR, Baird MS, Liu J, Liu Q.

Korean J Parasitol. 2016 Apr;54(2):139-45. doi: 10.3347/kjp.2016.54.2.139. Epub 2016 Apr 30.

13.

Could miltefosine be used as a therapy for toxoplasmosis?

Eissa MM, Barakat AM, Amer EI, Younis LK.

Exp Parasitol. 2015 Oct;157:12-22. doi: 10.1016/j.exppara.2015.06.005. Epub 2015 Jun 23.

PMID:
26112396
14.

Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.

Strobl JS, Cassell M, Mitchell SM, Reilly CM, Lindsay DS.

J Parasitol. 2007 Jun;93(3):694-700.

PMID:
17626366
15.

Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.

Mui EJ, Jacobus D, Milhous WK, Schiehser G, Hsu H, Roberts CW, Kirisits MJ, McLeod R.

Antimicrob Agents Chemother. 2005 Aug;49(8):3463-7.

16.

Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.

Maubon D, Bougdour A, Wong YS, Brenier-Pinchart MP, Curt A, Hakimi MA, Pelloux H.

Antimicrob Agents Chemother. 2010 Nov;54(11):4843-50. doi: 10.1128/AAC.00462-10. Epub 2010 Aug 16.

17.

Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum.

Stickles AM, de Almeida MJ, Morrisey JM, Sheridan KA, Forquer IP, Nilsen A, Winter RW, Burrows JN, Fidock DA, Vaidya AB, Riscoe MK.

Antimicrob Agents Chemother. 2015 Apr;59(4):1977-82. doi: 10.1128/AAC.04149-14. Epub 2015 Jan 20.

18.

Synthesis and anti-toxoplasmosis activity of 4-arylquinoline-2-carboxylate derivatives.

McNulty J, Vemula R, Bordón C, Yolken R, Jones-Brando L.

Org Biomol Chem. 2014 Jan 14;12(2):255-60. doi: 10.1039/c3ob41539b.

PMID:
24276426
19.

Dextran sulfate inhibits acute Toxoplama gondii infection in pigs.

Kato K, Murata Y, Horiuchi N, Inomata A, Terkawi MA, Ishiwa A, Ogawa Y, Fukumoto S, Matsuhisa F, Koyama K.

Parasit Vectors. 2016 Mar 9;9:134. doi: 10.1186/s13071-016-1421-9.

20.

1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase.

Szajnman SH, Rosso VS, Malayil L, Smith A, Moreno SN, Docampo R, Rodriguez JB.

Org Biomol Chem. 2012 Feb 21;10(7):1424-33. doi: 10.1039/c1ob06602a. Epub 2012 Jan 3.

Supplemental Content

Support Center